Acute Heart Failure, AE COPD, CAPD, Pulmonary Embolism, Severe Dyspnea
Conditions
Keywords
Dyspnea, Mortality
Brief summary
The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.
Detailed description
In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.
Interventions
OTHERPrognostic value of Biomarkers
Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
Sponsors
ThermoFisher Scientific Brahms Biomarkers France
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* tachypnea \> 25 /min or Pa02 \< 70 mmHg or SpO2 \< 93% * diagnosis suspected: CAP, PE,EACOPD, AHF
Exclusion criteria
* other cause of dyspnea, * unreachable on Day 30
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prognostic value of PCT, MR proADM, Mr pro ANP, Copeptin and pro endothelin in SOB | at Day 30 | all cause mortality or Intensive Care Unit(ICU) admission from inclusion to Day 30 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| establish the diagnostic value of PCT and MR pro ANP | at admission | Confirm the diagnostic value of PCT and it's level in sepsis and MR pro ANP in Heart failure |
Countries
France
Outcome results
None listed